Skip to main content

Cagent Vascular

Exploring Serration-Enhanced BTK Angioplasty: Investigators share case-based perspectives & trial experiences with the Serranator PTA Serration Balloon Catheter

https://evtoday.com/articles/2020-may/exploring-serration-enhanced-btk-angioplasty?c4src=current:feed

Cagent Vascular Announces FDA 510(k) Clearance for its Serranator Device for the Infrapopliteal Indication and Completion of its PRELUDE-BTK Clinical Trial Enrollment

https://cagentvascular.com/news/serranator-device

Cagent Vascular Initiates Enrollment of PRELUDE-BTK Study Using Serranator Device

https://cagentvascular.com/news/prelude-btk

Cagent Vascular Appoints Medical Device Industry Veteran Brian Walsh as Chairman of the Board

https://www.businesswire.com/news/home/20181009005252/en/Cagent-Vascular-Appoints-Medical-Device-Industry-Veteran

Cagent Vascular raises $11.87M to fund the growth and expansion of the SERRANATOR family of Percutaneous Transluminal Angioplasty (PTA) Serration Balloon Catheters

https://vascularnews.com/cagent-vascular-raises-us11-87m-funding/#:~:text=Cagent%20Vascular%20has%20announced%20the,in%20the%20Series%20A%20financing.

Cagent Vascular Announces CE Mark of Serranator, Next Generation Device for Vessel Dilatation in Peripheral Artery Disease Interventions

https://www.businesswire.com/news/home/20171120005812/en/Cagent-Vascular-Announces-CE-Mark-of-Serranator-Next-Generation-Device-for-Vessel-Dilatation-in-Peripheral-Artery-Disease-Interventions

Cagent Vascular completes enrolment of PRELUDE study using Serranator Alto device

https://vascularnews.com/cagent-vascular-completes-enrolment-of-prelude-study-using-serranator-alto-device/

M&L GROUP

We are a family investment firm that cultivates pioneering ventures into successful enterprises with passion, energy and integrity.

Hospitality
Healthcare
Shipping
Alternatives
Media room
About
Contact

Copyright © 2025 M&L Group. All Rights Reserved. | Legal.

Branding and website design by Stepworks